DelveInsight's“ Diarrhea Pipeline Insight 2025 ” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in the Diarrhea pipeline landscape. It covers the Diarrhea Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diarrhea Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Diarrhea Pipeline? Click here to explore the therapies and trials making headlines @ Diarrhea Pipeline Outlook Report

Key Takeaways from the Diarrhea Pipeline Report

• On 22 September 2025, Immuron Ltd . conducted a study to investigate if Travelan® protects healthy adult volunteers from moderate-to-severe diarrhea upon challenge with Enterotoxigenic Escherichia coli (ETEC) strain H10407.
• DelveInsight's Diarrhea Pipeline report depicts a robust space with 25+ active players working to develop 25+ pipeline therapies for Diarrhea treatment.
• The leading Diarrhea Companies such as RedHill Biopharma Limited, Puma Biotechnology, Inc., Hunazine Biotech, Vedanta Biosciences, Inc., Crinetics Pharmaceuticals Inc., MGB Biopharma Limited, Daewoong Pharmaceutical Co. LTD., Eveliqure Biotechnologies GmbH, Inmunova S.A., GlaxoSmithKline and others.
• Promising Diarrhea Therapies such as Carbowhite, Nitazoxanide, OPT-80, Racecadotril plus ORS, Rifaximin, Xifaxan®, Elsiglutide and others.

Want to know which companies are leading innovation in Diarrhea? Dive into the full pipeline insights @ Diarrhea Clinical Trials Assessment

The Diarrhea Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Diarrhea Pipeline Report also highlights the unmet needs with respect to the Diarrhea.

Diarrhea Overview

Diarrhea is having three or more loose or liquid stools (poos) in one day, or more frequently than normal. Diarrhea episodes are often caused by a stomach bug (gastroenteritis) and clear up on their own in a few days. However, there are many other causes of diarrhea. Most diarrhea is mild, but it can also be severe even needing admission to hospital. Diarrhea is the augmentation of water content in stools because of an imbalance in the normal functioning of physiologic processes of the small and large intestine responsible for the absorption of various ions, other substrates, and consequently water. Acute diarrhea is described as the acute onset of three or more loose or watery stools a day lasting for 14 days or less.

Diarrhea Emerging Drugs Profile

• VE303: Vedanta Biosciences, Inc.

VE303 is an orally administered, rationally-designed, defined bacterial consortium candidate being developed for high-risk Clostridioides difficile (CDI) infection. VE303 consists of 8 types of clonal human commensal bacteria strains selected for their ability to provide colonization resistance to C. difficile and manufactured under CGMP conditions. Currently, the drug is in clinical trial Phase III stage for the treatment diarrhea disease.

RHB-102: RedHill Biopharma Limited

RHB-102 is a proprietary, bimodal release, once-daily oral pill formulation of the antiemetic drug ondansetron, targeting several gastrointestinal indications. RHB-102 24 mg is intended to provide patients with relief from nausea and vomiting symptoms for a full 24-hour period with a single oral tablet. Currently, the drug is in clinical trial Phase II stage for the treatment diarrhea disease.

VR-AD-1005: Hunazine Biotech

VR-AD-1005, a novel antidiarrheal investigational drug for the innovative treatment of severe diarrhea of cholera. VR-AD-1005 is intended to work by reducing the volume of liquid stool produced by the intestine when suffering from the diarrheal pathogen. The drug works within the intestine without affecting its motility and does not induce constipation. Currently, the drug is in Phase II stage of its clinical trial for the treatment of severe diarrhea of cholera.

ShigETEC: Eveliqure Biotechnologies GmbH

ShigETEC is an orally administered vaccine that induces broad protection against Shigella in a serotype-independent fashion and additionally against ETEC, two major pathogens responsible for diarrhoeal diseases. Based on preclinical data generated by Eveliqure over the last 5 years, it has the potential to be a best-in-class diarrhoea vaccine that targets both travelers and populations in low- and middle-income countries. Currently, the drug is in clinical trial Phase I stage for the treatment of diarrhea disease.

If you're tracking ongoing Diarrhea Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Diarrhea Treatment Drugs

The Diarrhea Pipeline report provides insights into:-

• The report provides detailed insights about companies that are developing therapies for the treatment of Diarrhea with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diarrhea Treatment.
• Diarrhea Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Diarrhea Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diarrhea market.

Diarrhea Companies

RedHill Biopharma Limited, Puma Biotechnology, Inc., Hunazine Biotech, Vedanta Biosciences, Inc., Crinetics Pharmaceuticals Inc., MGB Biopharma Limited, Daewoong Pharmaceutical Co. LTD., Eveliqure Biotechnologies GmbH, Inmunova S.A., GlaxoSmithKline and others.

Diarrhea Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Diarrhea Products have been categorized under various Molecule types such as,

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

From emerging drug candidates to competitive intelligence, the Diarrhea Pipeline Report covers it all – check it out now @ Diarrhea Market Drivers and Barriers, and Future Perspectives

Scope of the Diarrhea Pipeline Report

• Coverage- Global
• Diarrhea Companies- RedHill Biopharma Limited, Puma Biotechnology, Inc., Hunazine Biotech, Vedanta Biosciences, Inc., Crinetics Pharmaceuticals Inc., MGB Biopharma Limited, Daewoong Pharmaceutical Co. LTD., Eveliqure Biotechnologies GmbH, Inmunova S.A., GlaxoSmithKline and others.
• Diarrhea Therapies- Carbowhite, Nitazoxanide, OPT-80, Racecadotril plus ORS, Rifaximin, Xifaxan®, Elsiglutide and others.
• Diarrhea Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Diarrhea Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research – discover what's next for the Diarrhea Treatment landscape in this detailed analysis @ Diarrhea Emerging Drugs and Major Players

Table of Contents